Hospital Injectable Products · LP-187
Haloperidol Injection
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-187Hospital Injectable Products
- Generic identity
- HaloperidolInjection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-187
- Generic ingredient
- Haloperidol
- Dosage form
- Injection
- Proposed strength
- 5 mg/mL
- Proposed pack
- Ampoule 1 mL; carton 10 ampoules
- Portfolio category
- Hospital Injectable Products
About Haloperidol
Haloperidol injection is a parenteral antipsychotic presentation used in defined supervised clinical settings. Its dopamine-related effects and safety profile differ from those of sedatives or anaesthetic medicines. A short-acting injection is also distinct from a depot formulation. The ingredient name must therefore be accompanied by the exact chemical form and presentation before a clinical or procurement decision is made.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Care requires a clear diagnosis and evaluation of reversible medical causes of behavioural change or agitation. Monitoring of consciousness, movement effects and cardiovascular status is important. The 5 mg/mL entry should not be interpreted as a long-acting depot or as universally authorized for any injection route. External references can discuss both immediate and extended-release products, so only formulation-relevant information should inform the final label review.
Important safety considerations
Acute dystonia, akathisia, parkinsonism and sedation can occur. Serious risks include QT-related arrhythmia, neuroleptic malignant syndrome and tardive dyskinesia. Older adults with dementia-related psychosis face increased mortality with antipsychotic treatment. Cardiac disease, electrolyte abnormalities, Parkinson disease and interacting medicines require assessment. Fever with rigidity, collapse, altered consciousness or severe abnormal movements need urgent clinical attention. Monitoring requirements depend on route and clinical circumstances.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The catalogue lists an injection concentration, but does not identify the salt. Confirm that the exact product is short-acting and verify approved routes, excipients and compatibility. A decanoate depot label must not be applied to this entry.
Professional preparation must follow the authorized label and local aseptic procedures. Confirm the correct container, concentration, route and expiry before use. Storage, transport, dilution compatibility and any period after opening or reconstitution require product-specific evidence; this page does not establish them.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm the diagnosis, specific injectable formulation, cardiac and movement risks, interactions and monitoring. Administration should follow a locally authorized protocol and verified label.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Haloperidol
- Dosage form / presentation
- Injection
- Catalogue strength
- 5 mg/mL
- Catalogue pack
- Ampoule 1 mL; carton 10 ampoules
- Portfolio category
- Hospital Injectable Products
Layer 02
Unresolved product-specific fields
- The injection record does not identify the haloperidol salt. Do not infer haloperidol lactate, decanoate/depot character, authorised route or compatibility from the ingredient name alone.
- External short-acting injection labels illustrate why exact chemical form and route matter; they are not Luang Pharma formulation evidence.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Haloperidol Injectiongovernment-hosted medicine monograph
- DailyMed: haloperidol lactate injection 5 mg/mL — external reference labelgovernment-hosted external product label
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Sterile product specification confirming active chemical form, concentration, container/volume, authorised route(s), excipients/preservatives, compatibility and preparation/administration controls.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-187, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
- MedlinePlus: Haloperidol Injection — ingredient/formulation reference
- DailyMed: haloperidol lactate injection 5 mg/mL — external reference label
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-187.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.